List view / Grid view
University of Chicago researchers have developed a scalable nanoparticle platform that self-assembles with just a temperature change – enabling safe, solvent-free delivery of proteins and RNA for vaccines and therapies.
Porosome Therapeutics have announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
Japanese researchers have engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively, resulting in stronger immune responses and tumour suppression in mice.
Scientists at Ghent University have discovered that a simple combination of vitamin B1 and glucose could drastically improve survival in sepsis – a life-threatening condition responsible for millions of deaths each year.
Cambridge researchers have discovered a new drug that could dramatically improve stroke recovery by reducing brain damage caused when blood flow is restored.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
Gene therapy’s progress depends on reliable supply chains and efficient manufacturing. In this episode, we explore the challenges and strategies involved in plasmid production - an essential component in advancing life-changing therapies.
A new weekly injection developed by University of South Australia scientists could change Parkinson’s treatment by replacing the need for multiple daily pills – potentially helping millions of patients worldwide.
Scientists have created a new class of ultra-stable chiral molecules – a discovery that could lead to more precise drug design by preventing potentially harmful molecular “flipping” over time
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
7 July 2025 | By Molecular Devices
Expert insights reveal how 3D cellular models are revolutionising preclinical testing and clinical translation.
As ethical pressures and new regulations shake up preclinical research, the industry faces a turning point: can we finally move beyond non-human primates? Dr Mariana Argenziano, Associate Director Manufacturing Technologies at Ncardia, discusses the innovations reshaping drug development and what’s coming next.
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
